Literature DB >> 6427817

Dose-response analysis of the behavioral effects of diazepam: II. Psychomotor performance, cognition and mood.

M M Ghoneim, S P Mewaldt, J V Hinrichs.   

Abstract

The psychomotor, cognitive, and mood effects of orally administered diazepam and placebo were measured over approximately equal to 3.5 h. A total of 120 volunteers were assigned to 12 groups of 10 each, representing the combination of four treatments (placebo, 0.1, 0.2, and 0.3 mg/kg diazepam) and three testing sessions (7 AM, 1 PM, and 7 PM). A variety of cognitive tasks, tapping and postural stability tests, and a mood evaluation scale were used. Psychomotor and cognitive functions showed consistent dose-response effects, while for subjective evaluations, the only effect of dose level was in the duration of sedation. The pattern of impairment of cognitive functions suggests that the drug affects speed rather than accuracy, and it primarily blocks acquisition of new information or skills. Use of repeated testing may therefore be necessary to detect subtle drug effects. Subjects reported no tranquilization , which suggests that the anxiolytic action of the drug cannot be studied in healthy volunteers. There was no circadian influence on the actions of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427817     DOI: 10.1007/bf00427673

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  HUMAN ACQUISITION OF CONCEPTS FOR SEQUENTIAL PATTERNS.

Authors:  H A SIMON; K KOTOVSKY
Journal:  Psychol Rev       Date:  1963-11       Impact factor: 8.934

2.  The residual effects of flurazepam.

Authors:  A J Bond; M H Lader
Journal:  Psychopharmacologia       Date:  1973-09-28

3.  Acute adaptation to the effects of alcohol.

Authors:  P M Hurst; S K Bagley
Journal:  Q J Stud Alcohol       Date:  1972-06

4.  The action of sedatives on brain stem oculomotor systems in man.

Authors:  H Norris
Journal:  Neuropharmacology       Date:  1971-03       Impact factor: 5.250

5.  Dose-response analysis of the effects of tetrahydrocannabinol in man.

Authors:  G F Kiplinger; J E Manno; B E Rodda; R B Forney
Journal:  Clin Pharmacol Ther       Date:  1971 Jul-Aug       Impact factor: 6.875

6.  Dose-response analysis of the behavioral effects of diazepam: I. Learning and memory.

Authors:  M M Ghoneim; J V Hinrichs; S P Mewaldt
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Evaluation of instrumented force platform as a test to measure residual effects of anesthetics.

Authors:  K Korttila; M M Ghoneim; L Jacobs; R S Lakes
Journal:  Anesthesiology       Date:  1981-12       Impact factor: 7.892

8.  Effects of marijuana on human reaction time and motor control.

Authors:  T O Kvålseth
Journal:  Percept Mot Skills       Date:  1977-12

9.  Advances in human chronopharmacology.

Authors:  A Reinberg
Journal:  Chronobiologia       Date:  1976 Apr-Jun

10.  Memory and performance effects of single and 3-week administration of diazepam.

Authors:  M M Ghoneim; S P Mewaldt; J L Berie; J V Hinrichs
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more
  15 in total

1.  Administration of the benzodiazepine midazolam increases tau phosphorylation in the mouse brain.

Authors:  Robert A Whittington; László Virág; Maud Gratuze; Hilana Lewkowitz-Shpuntoff; Mehdi Cheheltanan; Franck Petry; Isabelle Poitras; Françoise Morin; Emmanuel Planel
Journal:  Neurobiol Aging       Date:  2018-11-08       Impact factor: 4.673

2.  Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines.

Authors:  J Ingum; R Bjørklund; A Bjørneboe; A S Christophersen; E Dahlin; J Mørland
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  The effects of fall-risk-increasing drugs on postural control: a literature review.

Authors:  Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

4.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

5.  Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93 426: antagonism of lormetazepam's psychotropic effects.

Authors:  T Duka; D Goerke; R Dorow; L Höller; K Fichte
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Cognition-impairing effects of benzodiazepine-type drugs: role of GABAA receptor subtypes in an executive function task in rhesus monkeys.

Authors:  Leah Makaron; Casey A Moran; Ojas Namjoshi; Sundari Rallapalli; James M Cook; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

7.  Effects of repeated doses of fluvoxamine, mianserin and placebo on memory and measures of sedation.

Authors:  H V Curran; P Shine; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests.

Authors:  A Vermeeren; J L Jackson; N D Muntjewerff; P J Quint; E M Harrison; J F O'Hanlon
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 9.  Biomarkers for the effects of benzodiazepines in healthy volunteers.

Authors:  S J de Visser; J P van der Post; P P de Waal; F Cornet; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

10.  Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.

Authors:  A Patat; M C Perault; B Vandel; N Ulliac; I Zieleniuk; P Rosenzweig
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.